mercaptopurine / Generic mfg. - LARVOL DELTA

Thiopurine pharmacogenomic landscape in India: TPMT and NUDT15 allele frequencies (ASH 2025) - "Thiopurines—such as azathioprine, mercaptopurine, and thioguanine—are commonly used in hematology as immunosuppressants and chemotherapeutic agents. We also identified rare, potentially deleterious TPMT variants that are absent or underrepresented in global reference datasets, underscoring the value of population-specific pharmacogenomic profiling. Our findings support pre-treatment NUDT15 genotyping (and TPMT where indicated) with genotype-informed dose adjustment and early monitoring to reduce myelosuppression-related treatment interruptions."

Biomarker • NUDT15

Effect and mechanism of allopurinol in ALL maintenance therapy: Reducing hepatotoxicity and improving myelosuppression effect via TPMT inhibition and increased DNA-thioguanine levels (ASH 2025) - "Introduction: 6-Mercaptopurine (6-MP) based-maintenance therapy is essential to cure acute lymphoblastic leukemia (ALL). In conclusion, intensifying 6-MP dosing does not achieve adequate myelosuppression effect, but primarily increases the risk of hepatotoxicity by experiencing skewed metabolism. Low-dose 6-MP combined with allopurinol, rather than intensifying 6-MP dose, could be an alternative strategy for better efficacy and lower risk of hepatotoxicity."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Hepatology • Leukemia • NUDT15

Risk of lymphoma with antimetabolite and biologic combinations: A pharmacovigilance analysis using the FDA adverse event reporting system database (ASH 2025) - "Our study compared combinations of antimetabolites—such asmethotrexate (MTX), mercaptopurine (6-MP), and azathioprine (AZA)—with anti-TNF agents includinginfliximab, adalimumab, certolizumab, and golimumab, to determine which regimens were most stronglyassociated with lymphoma. Clinicians should carefully weigh the risks and benefits of combination immunosuppressivetherapy, especially when prescribing infliximab with MTX or 6-MP, given the observed synergistic increasein risk for lymphoma."

Adverse events • Hematological Malignancies • Immunology • Lymphoma • ROR1

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry (ASH 2025) - P=N/A | "BSCincluded transfusions and other supportive measures, with or without oral cytoreductive agents (e.g.,hydroxyurea, melphalan, mercaptopurine or thioguanine). Approximately 8% of elderly AML patients treated exclusively with BSC show unexpectedly long survival,consistent with an indolent clinical course, reflecting that in the absence of more efficacious therapeuticregimens, some patients could benefit from less invasive approaches. Easily measurable clinicalparameters such as bone marrow blasts, platelet count, and serum albumin may help identify thesepatients. Further prospective and molecular studies are warranted to validate these findings andelucidate the biological underpinnings of iAML."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • FLT3 • NPM1

Prevalence of TPMT and NUDT15 diplotypes in Mexican children with B-cell acute lymphoblastic leukemia (ASH 2025) - "This study demonstrates that approximately 28% of Mexican pediatric B-ALL patients arepredicted to have reduced enzymatic activity in TPMT, NUDT15, or both, placing them at increased riskfor mercaptopurine-induced myelotoxicity. Pre-emptive genotyping of TPMT and NUDT15 in Mexican B-ALL patients is essential for minimizing treatment-related toxicity, improving clinical outcomes, andadvancing precision medicine strategies."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • NUDT15

Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study (ASH 2025) - P=N/A | "Patients received theTKI combine with low-dose chemotherapy (overembatinib, vincristine, prednisone and venetoclax) asinduction therapy, followed by 1-2 cycles of TKI combine with oral regimens (olverembatinib, venetoclax,and prednisone) as outpatient consolidation treatment. Then, a single infusion of murine-derived second-generation CD19-directed CAR T-cells (with a 4-1BB co-stimulatory domain) during first remission.Maintenance therapy included alternating administrations of vincristine, methotrexate, mercaptopurine,prednisone, venetoclax, and oral TKI. Intrathecal methotrexate (MTX), cytarabine, and dexamethasonewere administered for central nervous system (CNS) prophylaxis... Front-line CAR-T therapy as consolidation in newly diagnosed Ph⁺B-ALL patients is a safe andeffective regimen, resulting in deep remission without the need for intensive chemotherapy, and offeringhope for sustained remission.Key wordsAcute lymphoblastic leukemia, Front-line CAR-T,..."

Clinical • IO biomarker • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • ABL1 • BCR

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) (ASH 2025) - P3 | "Induction therapy comprised 3 cycles of VD or VDP: vincristine1.4 mg/m2 (maximum 2 mg) on days (D) 1, 8, 15, and 22; dexamethasone 10 mg on D1–14, 5 mg on D15–21, and 2.5 mg on D22–28; and daunorubicin 25 mg/m2 (maximum 40 mg; 20 mg for patients ≥ 70 years)on D1–3. Consolidation alternated 3 cycles of high-dose methotrexate (1.0 g/m2, 1 day) with 3 cycles ofcytarabine (1,000 mg/m2 every 12 hours; 250 mg/m2 every 12 hours for patients > 60 years, 3 days).Maintenance therapy of mercaptopurine plus methotrexate and VP was alternated for 12 cycles atstandard dosages...The regimenextended the window for further treatment and demonstrated a favorable safety profile. (NCT06051409; HQP1351AG301)."

Clinical • P3 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Leukopenia • Neutropenia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia • ABL1 • BCR • CDKN2A • CDKN2B • EBF1 • ETV6 • IKZF1 • PAX5

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis (ASH 2025) - P2 | "We,therefore, conducted a propensity matched analysis comparing the outcomes of pts with ND Ph-negative(-) B-ALL who received HCVAD vs. HCVAD and sequential blina.MethodsPts with ND Ph- B-ALL 18-60 years who received HCVAD with/without an anti-CD20 antibody(rituximab/ofatumumab) (NCT01363128) or HCVAD and sequential blina with/without inotuzumab(NCT02877303) were included...The duration of maintenance was reducedfrom 30 cycles of POMP (6-mercaptopurine, vincristine, methotrexate, prednisone) to 12 cycles with 1course of blina every third course for a total of 3 courses of blina...For matched Ph-like, the 3- and 5-year EFS rates were 63% and 50% vs. 83% and83% for HCVAD vs. HCVAD/blina, respectively (p=0.271), with 3- and 5-year OS rates of 63% vs. 100%respectively (p=0.099).MVA identified age (EFS HR 1.02 p=0.003 OS HR 1.024 p=0.013), smoking (EFS HR 1.8 p=0.003 OS HR 1.8p=0.01), BMI (EFS HR 1.06 p<0.001 OS HR 1.04 p=0.017), ECOG (EFS HR 2.1 p=0.01), KMT2Ar (EFS..."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • KMT2A

Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study (ASH 2025) - P=N/A | "These patients initially received pediatric-inspired induction therapy, which included acombination of vincristine, idarubicin, cyclophosphamide, asparaginase, prednisone, and venetoclax,followed by 1-2 consolidation cycles (for further details, see ClinicalTrials.gov Identifier: NCT06481241).Subsequently, they received a single infusion of murine-derived second-generation 4-1BB-CD19 CAR-T asconsolidation therapy during the first remission period. Maintenance therapy consisted of alternatingadministrations of vincristine, methotrexate, mercaptopurine, prednisone, and oral venetoclax.Intrathecal methotrexate (MTX), cytarabine, and dexamethasone were administered for central nervoussystem (CNS) prophylaxis. As of the cutoff date in February 2025, 44 patients were enrolled in the trial and received CD19CAR-T therapy as consolidation... First-line CAR-T therapy as consolidation treatment can effectively eradicate leukemia cells toa deep level and demonstrates a..."

Clinical • IO biomarker • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • BCOR • CD22 • IKZF1 • KMT2A • PAX5 • TP53 • ZNF384

Therapeutic ANC attainment during maintenance chemotherapy for pediatric acute lymphoblastic leukemia (ASH 2025) - "Pediatric ALL treatmentrequires a maintenance phase which includes daily oral mercaptopurine (6-MP) and weekly oralmethotrexate (MTX)...Patients with Philadelphia + B-ALL or those receiving ruxolitinib were excluded...Target ANC was maintained for only one-third (33.3%) of the maintenance period. Although low targetANC attainment may be related to patient factors such as oral chemotherapy adherence, the meanduration of oral 6-MP/MTX held as well as lower target ANC attainment in patients receiving treatmentoff a clinical trial suggests that medical team prescribing practices may have also contributed to thisfinding. Higher target ANC attainment among those enrolled on therapeutic clinical trials may be due toincreased likelihood of protocol-directed dose adjustments and closer ANC monitoring."

Clinical • Acute Lymphocytic Leukemia • Febrile Neutropenia • Hematological Malignancies • Leukemia • Pediatrics

Atypical hemolytic uremic Syndrome Triggered by malignancy and drug exposure: A systematic review and meta-analysis (ASH 2025) - "Tacrolimus was the mostreported drug trigger (n=6)followed by gemcitabine (n=5), vincristine (n=5), bevacizumab (n=3), carfilzomib (n=3), 6-mercaptopurine(n=2), methotrexate (n=2), and mitomycin (n=2). Aflibercept, bactrim, bleomycin, capecitabine, cisplatin, cyclophosphamide, cytarabine,dasatinib, deferasirox, dinutuximab, estarylla, ketoprofen, L-asparaginase, modakafusp alfa, PEG-asparaginase, sunitinib, syntheticpsychoactive drugs, tamoxifen, and topotecan were reported as potential triggers for aHUS in one patient each...The pooled rate of treatment with eculizumab was 74% (95% CI, 0.629-0.842, p < 0.01, I2 = 72%),and the pooled rate of renal recovery was 65% (95% CI, 0.525-0.761, p < 0.01, I2 = 55%)...AKI and hematological abnormalities in these patients should prompt an emergent work-up and treatment. Current evidenceis primarily derived from case reports, so prospective trials are necessary to establish the incidence, associations, triggers, and outcomes..."

Retrospective data • Review • Acute Kidney Injury • Acute Lymphocytic Leukemia • Anemia • Atypical Hemolytic Uremic Syndrome • B Acute Lymphoblastic Leukemia • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Complement-mediated Rare Disorders • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Hodgkin Lymphoma • Leukemia • Lung Cancer • Lymphoma • Multiple Myeloma • Nephrology • Neuroblastoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor • Thrombocytopenia • Urothelial Cancer

Clinical spectrum of noonan syndrome–associated myeloproliferative disorder (ASH 2025) - "Low-dose chemotherapy was administered to 7 patients (6-mercaptopurine[n = 3], cytarabine [n = 3], and azacitidine [n = 2]). Although most cases spontaneously resolve, some patients may develop"true JMML," through secondary genetic events, underscoring the necessity to clearly distinguish thesecases from typical infantile NS-MPD. These findings highlight the need for careful genetic evaluation andlong-term hematological monitoring in the management of patients with NS."

Clinical • Chronic Myelomonocytic Leukemia • Genetic Disorders • Heart Failure • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Juvenile Myelomonocytic Leukemia • Leukemia • Myeloproliferative Neoplasm • Thrombocytopenia • CSF2 • KRAS • NRAS • PTPN11 • RIT1

Real-world insights into ATRA-based maintenance therapy and prognostic markers of relapse in acute promyelocytic leukemia (ASH 2025) - "We aimed to evaluate thelong-term clinical impact of ATRA-based maintenance therapy and other prognostic factors of relapse in amulticenter real-world cohort of Korean APL patients treated with ATRA+Idarubicin (AIDA) protocol.We retrospectively analyzed 286 APL patients who achieved complete remission following AIDA-basedchemotherapy from 2002–2024 across five South Korean tertiary centers...Key prognostic variables including maintenance therapy, Sanz risk, MRD, FLT3mutation status, and sex were assessed.252 patients (88.1%) received maintenance following consolidation, whereas 34 patients (11.9%) did not.Among those who received maintenance, 210 patients (73.4%) were treated with ATRA alone, while 42patients (14.7%) received ATRA in combination with low-dose chemotherapy (6-mercaptopurine andmethotrexate)...Post-consolidation MRD positivity emerged as the most significant predictor of relapse in APL, whileATRA-based maintenance therapy did not confer a significant..."

Biomarker • Clinical • Real-world • Real-world evidence • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • FLT3

Subsequent Meningiomas Among Survivors of Childhood Cancer. (PubMed, JAMA Netw Open) - "An increased risk of meningioma was associated with higher doses of cranial radiation therapy (eg, HR, 125.3 [95% CI, 58.1-270.5]), younger age at primary cancer diagnosis (eg, 0 to 4 years: HR, 4.0 [95% CI, 2.4-6.1]), female sex (HR, 1.6 [95% CI, 1.3-1.9]), and exposure to platinum, 6-mercaptopurine, and intrathecal chemotherapy, and a lower risk was associated with non-Hispanic Black race (HR, 0.5 [95% CI, 0.3-1.0]) and exposure to alkylating agents (HR, 0.6 [95% CI, 0.5-0.8])...Meningiomas have a relatively high incidence and mortality for childhood cancer survivors. Results from this study could justify screening for meningiomas in high-risk populations."

Journal • Retrospective data • Brain Cancer • Meningioma • Oncology • Solid Tumor

Profound hematologic instability in consanguinity-associated familial hemophagocytic lymphohistiocytosis: a pediatric case report. (PubMed, Ann Med Surg (Lond)) - "Patient was referred to the oncology department and started on initial chemotherapy with vinblastine, prednisolone, and mercaptopurine and continuation chemotherapy therapy with vinblastine. Advances in genetic testing and treatment modalities are critical for improving outcomes and long-term prognosis in FHL. Continued research is essential to refine diagnostic criteria and therapeutic strategies for optimal patient care."

Journal • Cough • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Leukopenia • Oncology • Pediatrics • Pneumonia • Rare Diseases • Respiratory Diseases • Thrombocytopenia

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (ASH 2023) - "Patients received mini-Hyper-CVD (mHCVD, cyclophosphamide 150mg/m2 q12h D1-3, dexamethasone 20mg daily D1-4, 11-14, and vincristine 2mg D1, 8 alternating with methotrexate (MTX) 250mg/m2 D1 & cytarabine 500mg/m2 q12h D2, 3) for up to 8 cycles. Eight doses of intrathecal (IT) MTX /cytarabine were given for CNS prophylaxis; patients with CNS disease had IT hydrocortisone, MTX, and cytarabine twice weekly till CNS clearance, then weekly x4. Eight doses of rituximab 375mg/m2 were given on D1, 8 of C1-4 if CD20 was ≥20% by flow cytometry...Ursodeoxycholic acid was given to all patients...Maintenance was initially with vincristine 2mg D1, prednisolone 50mg daily D1-5, 6-mercaptopurine 50mg BID & MTX 10mg/m2 weekly (POMP) for three years...Conclusion Older patients with ND Ph-negative ALL treated with mHCVD plus InO, with or without blina had excellent response rates and deep remissions. However, further adjustment of the regimen is needed, especially in patients ≥70..."

Clinical • P2 data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Septic Shock • CD20 • TP53

Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update (ASH 2024) - "The chemotherapy backbone was mHCVD (mHCVD : cyclophosphamide 150mg/m2 q12h [day] D1-3, dexamethasone 20mg/day D1-4, 11-14, and vincristine 2 mg D1, 8; alternating with methotrexate (MTX) 250mg/m2 D1 & cytarabine 500mg/m2 q12h D2, 3) for up to 8 cycles (C). 12 doses of intrathecal IT MTX /cytarabine were given for CNS prophylaxis; pts with CNS disease had IT hydrocortisone, MTX, and cytarabine 2/week till CNS clearance, then weekly x 4. 8 doses of rituximab 375mg/m2 were given on D1, 8 of C1-4 if CD20 was ≥20% by flow cytometry (FCM)...Ursodeoxycholic acid was given to all pts...Maintenance was initially with vincristine 2mg D1, prednisolone 50mg daily D1-5, 6-mercaptopurine 50mg BID & MTX 10mg/m2 weekly (POMP) for 3 years...Conclusion : mHCVD-InO ± Blina is an efficacious and tolerable regimen with promising PFS and OS benefit even on long-term F/U. Further reduction of chemo doses and assessment of mutations that increase risk of myeloid neoplasms,..."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • CD20 • CRLF2 • KMT2A • TP53

Non-alcoholic fatty liver disease in patients with Crohn's disease: differences in active and inactive stages. (PubMed, Arab J Gastroenterol) - "Approximately one-fifth of patients with CD developed NAFLD, mainly lean NAFLD. NAFLD in active and inactive CD exhibits different characteristics and risk factors, suggesting that the underlying mechanisms of NAFLD in different CD activities may differ. Most of CD patients with NAFLD were alleviated after CD-related treatment."

Journal • Crohn's disease • Gastroenterology • Hepatology • Immunology • Inflammatory Bowel Disease • Metabolic Dysfunction-Associated Steatotic Liver Disease • CRP

Preemptive NUDT15 Genotyping and Its Impact on Febrile Neutropenia in Pediatric Patients With Acute Lymphoblastic Leukemia in Taiwan. (PubMed, J Pediatr Hematol Oncol) - "Multivariate analysis was performed, and the dosage was adjusted for age, sex, and mercaptopurine...Preemptive NUDT15 genotyping did not significantly reduce febrile neutropenia episodes in our cohort of pediatric patients with ALL, although it allowed a potential reduction in HR patients. Clinicians should consider preemptive testing, particularly in HR and VHR patient groups, to optimize ALL treatments and reduce adverse events."

Journal • Acute Lymphocytic Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Pediatrics • NUDT15

ABX464-103: Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P2 | N=355 | Completed | Sponsor: Abivax S.A. | Phase classification: P2b ➔ P2 | N=254 ➔ 355

Enrollment change • Phase classification • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

An Advanced Fluorescent Molecularly Imprinted Sensor Based on Carbon Quantum Dots for Highly Sensitive Detection of 6-Mercaptopurine. (PubMed, J Fluoresc) - "It exhibited strong anti-interference capability, excellent reproducibility and stable fluorescence performance. When applied to the detection of Mercaptopurine tablets, the method achieved recovery rate of 97.80%-108.63%, providing a highly sensitive and cost-effective analytical approach for clinical drug monitoring."

Journal • Oncology

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between TPMT/NUDT15 and thiopurines. (PubMed, Eur J Hum Genet) - "The current guideline describes the gene-drug interactions for TPMT, NUDT15 and thiopurines (azathioprine, 6-mercaptopurine and thioguanine). For TPMT or NUDT15 IM treated for leukaemia, starting with the normal dose can be considered and then decrease the dose to the advised dose described above in case toxicities occur. For NUDT15 PM reduced starting dose is advised only if an alternative is not possible, due to a higher uncertainty in the calculated dose reduction for NUDT15 PM than for TPMT PM.DPWG classifies genotyping for TPMT and NUDT15 "essential" before thiopurine initiation."

Biomarker • Journal • CNS Disorders • Depression • Hematological Malignancies • Leukemia • Oncology • Psychiatry • NUDT15

Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia (ASH 2024) - "Patients who experienced early failure were more likely to have received pre-tisa-cel inotuzumab ozogamicin (InO, 7/13 (54%) vs 6/39 (21%), p= .01)...The most frequent used drugs in salvage therapy were steroids, vinca alkaloids, and 6-mercaptopurine. InO was given in 14 patients, blinatumomab in 15 patients, and 10 patients received a second CAR-T infusion...Key factors influencing outcomes include the loss of CD19 and disease aggressiveness, such as tumor burden prior to tisa-cel treatment and previous exposure to InO. Additionally, bridging to HSCT can offer a curative option, although it carries a high risk of toxicity as reported in advanced disease stages."

Clinical • IO biomarker • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Leukemia • Oncology • CD19 • KMT2A • PBX1 • TCF3 • TP53

Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study (ASH 2023) - P1/2 | "In this study, bortezomib and vorinostat were incorporated into an ALL chemotherapy backbone containing dexamethasone, mitoxantrone, and pegasparaginase during induction and reinduction chemotherapy cycles...Following induction intensification with cyclophosphamide, cytarabine, and mercaptopurine, 77% and 66% of all patients and KMT2Ar patients respectively were MRD negative at the time of count recovery...Although the study was not powered to evaluate outcomes, EFS and OS in KMT2Ar patients suggest a clinical signal worth pursuing given the low proportion of patients transplanted in first remission. The successor study, TINI 2 (NCT05848687), will build upon the bortezomib/vorinostat backbone by incorporating 2 cycles of blinatumomab and the menin inhibitor ziftomenib in combination with chemotherapy during reinduction."

Clinical • Acute Lymphocytic Leukemia • Anorexia • Cardiovascular • Dyslipidemia • Febrile Neutropenia • Hematological Malignancies • Hypertension • Hypertriglyceridemia • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock • AFF1 • KMT2A • MLLT3

Does CytoSorb Interfere with Immunosuppression? A Pharmacokinetic and Functional Evaluation. (PubMed, Pharmaceutics) - " In this ex vivo study, we investigated the adsorption of five immunosuppressants-cyclosporine A, tacrolimus, methylprednisolone, mycophenolic acid, and 6-mercaptopurine-using a scaled-down CytoSorb hemoadsorption circuit and compared results to chronic and acute dialysis. However, short-term treatment appears to have minimal impact on immunosuppressive function. These findings support the cautious use of CytoSorb in transplant settings but highlight the need for in vivo confirmation."

Journal • PK/PD data • Immunology • Transplantation • CXCL8 • IL1B • IL6 • TNFA